Cidara Therapeutics (CDTX) Registration Filing summary

Company overview and business model

• Focuses on developing drug-Fc conjugate (DFC) immunotherapies using the proprietary Cloudbreak platform, targeting serious diseases by combining disease inhibition and immune system engagement.

• Lead asset CD388 is a DFC for universal influenza prophylaxis, reacquired from Janssen in April 2024, now the sole R&D focus.

• Divested rezafungin assets in April 2024 to Napp, classifying the sale as discontinued operations and shifting all resources to Cloudbreak programs.

• Operates as a smaller reporting company, providing less public disclosure than larger peers.

Financial performance and metrics

• Reported an accumulated deficit of $559.0 million as of September 30, 2024, with ongoing net losses expected.

• Cash and cash equivalents were $127.4 million at September 30, 2024, with $105.0 million in gross proceeds from a November 2024 private placement.

• For the nine months ended September 30, 2024: $1.3 million in collaboration revenue, $84.9 million in acquired IPR&D expenses (upfront payment to Janssen), $25.0 million in R&D expenses, and $13.3 million in SG&A expenses.

• Net cash used in operating activities for the nine months ended September 30, 2024 was $147.1 million, primarily due to the Janssen payment and prepayments for the CD388 Phase 2b study.

• No outstanding loan balances as of September 30, 2024.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; only nominal proceeds from warrant exercises.

• Proceeds from the April 2024 Series A Private Placement ($240.0 million) and November 2024 Private Placement ($105.0 million) are allocated to fund the reacquisition and development of CD388 and support ongoing operations.

• $85.0 million of Series A proceeds used for the Janssen License Agreement upfront payment; remaining funds support CD388 development and operational liquidity.